The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: A retrospective database analysis

Current Medical Research and Opinion, Supplement

Volumn 23, Issue 1, 2007, Pages

  Poole, Chris D ^a   Tetlow, Tony ^a   McEwan, Phil ^b   Holmes, Paul ^c   Currie, Craig J ^b,d  

^a Threesixtydegree Research Ltd   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c Sanofi Aventis UK   (United Kingdom)

^d Medicentre   (United Kingdom)

Author keywords

Basal insulin; Cost; Hypoglycaemia; Monitoring; Oral hypoglycaemic agents; Type 1 diabetes; Type 2 diabetes

Indexed keywords

INSULIN DETEMIR; INSULIN GLARGINE; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG COST; DRUG EXPOSURE; FEMALE; GENERAL PRACTICE; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; RETROSPECTIVE STUDY; UNITED KINGDOM;

EID: 33947386544     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X167589     Document Type: Article

References (23)

1. Rosenstock J, Park G, Zimmerman J. Basal Lantus (HOE901) versus NPH insulin in patients with type 1 diabetes or multiple daily insulin regimens. Diabetes Care 2000;23:1137-42
2. Ratner R, Hirsch IB, Niefing JL, et al. Less hypoglycaemia with Lantus in intensive insulin therapy for Type 1 diabetes. Diabetes Care 2000;23:639-43
3. NICE appraisal no. 53. [http://www.nice.org.uk/page.aspx?o=TA053] (accessed 28th April 2006)
4. Warren E, Weatherley-Jones E, Chilcott J, Beverley C. Systematic review and economic evaluation of a long acting insulin analogueue, insulin glargine. Health Technol Assess 2004;8: No.45.
5. Longson C. Proposal to update the current guidance on insulin glargine in a guideline, and appraisal insulin detemir through the single technology appraisal process. Public communication, 9th January 2006.
6. Pieber TR, Treichel HC, Robertson LI, et al. Insulin detemir plus insulin aspart is associated with less risk of major as well as nocturnal hypoglycaemia than insulin glargine plus insulin aspart at comparable levels of glycaemic control in type 1 diabetes. Diabetologia 2005;48(Suppl 1):A92
7. Currie CJ, Poole CD, Tetlow T, et al. The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Cur Med Res Opin 2007;23(Suppl 1)
8. Summary of Product Characteristics for Lantus 100 IU/ml. 〈http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid= 8962〉 (last accessed 20th June 2006).
9. Summary of Product Characteristics for Levemir Cartridge 100 U/ml, Levemir Pre-filled Pen 100 U/ml. 〈http://emc.medicines.org.uk/emc/assets/c/ html/displaydoc.asp?documentid=14584〉 (last accessed 20th June 2006)
10. Misbin RI. Medical review of insulin detemir (NDA 021-536). Centre for Drug Evaluation & Research, US Food and Drug Administration. 9th June 2005. 〈http://www.fda.gov/cder/foi/nda/2005/021-536_Levemir_medr.PDF〉 (last accessed: 20th June 2006)
11. Lechleitner M, Roden M, Haehling E, Meuller M. Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in Type 2 diabetes mellitus. Wien Klin Wochenschr 2005;117:593-8
12. THIN [http://www.epic-uk.org/thin.htm] (accessed 21st April 2006]
13. GRRD [http://www.gprd.com/home/] (accessed 21st April 2006)
14. BMA & RPSGB. British National Formulary No. 51. 〈www.bnf.org/ bnf〉 (last accessed: 20th June 2006)
15. Health & Social Care Information Centre. Prescription Cost Analysis 2005 for England. 〈http://www.ic.nhs.uk/pubs/prescostanalysis2005/pcaexcel/ file〉 (last accessed: 20th June 2006)
16. UK Drug Tariff, December 2005 〈http://www.ppa.nhs.uk/edt/ December_2005/mindex.htm〉 (last accessed 20th June 2006)
17. Chemist & Druggist (April 2006). CMP Information Ltd. 〈http://www.candnet.com/login.asp〉 (last accessed, 30th June 2006).
18. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycaemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176-80
19. Clarke PM, Gray AM, Briggs A, et al. UK Prospective Diabetes Study (UKDPS) Group. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59
20. Scholtz HE, Pretorius SG, Wessels DH, et al. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in heakhy volunteers using a euglycaemic clamp technique. Diabetologia 2005;48:1988-1995
21. Plank J, Bodenlenz MR, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005;28:1107-1112
22. Evans JMM, Donnan PT, Morris AD. Adherence to oral hypoglycaemic agents prior to insulin therapy in Type 2 diabetes. Diabetic Medicine 2002,19:685-688
23. Morris AD, Boyle DIR, McMahon AD, et al. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Lancet 1997;350:1505-10